Janssen Announces Positive Topline Results for JNJ-2113—A Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Trial results for JNJ-2113 demonstrated a profile that supports its advancement into Phase III clinical development for moderate-to-severe plaque psoriasis in adult patients.